{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:04:54Z","timestamp":1793714694461,"version":"4.6.1"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.molmet.2020.101102","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T10:34:26Z","timestamp":1602671666000},"page":"101102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1578,"special_numbering":"C","title":["GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-6954","authenticated-orcid":false,"given":"Michael A.","family":"Nauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-6846","authenticated-orcid":false,"given":"Daniel R.","family":"Quast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-6491","authenticated-orcid":false,"given":"Jakob","family":"Wefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juris J.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2020.101102_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Letters"},{"key":"10.1016\/j.molmet.2020.101102_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101102_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2020.101102_bib4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diab.39.11.1320","article-title":"Reduced insulinotropic effects of glucagonlike peptide 1-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas","volume":"39","author":"Suzuki","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101102_bib6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/(SICI)1096-9136(1998110)15:11<937::AID-DIA701>3.0.CO;2-0","article-title":"Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients","volume":"15","author":"Nauck","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib9","first-page":"E 458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.molmet.2020.101102_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.molmet.2020.101102_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101102_bib13","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2020.101102_bib14","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"G\u00f6ke","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2020.101102_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib16","doi-asserted-by":"crossref","first-page":"154031","DOI":"10.1016\/j.metabol.2019.154031","article-title":"The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship","volume":"103","author":"Nauck","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib19","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.molmet.2020.101102_bib20","doi-asserted-by":"crossref","first-page":"R 211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.molmet.2020.101102_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/dmrr.2647","article-title":"Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects","volume":"31","author":"Becker","year":"2015","journal-title":"Diabetes Metabolism Research Reviews"},{"key":"10.1016\/j.molmet.2020.101102_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0091270006288215","article-title":"An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide","volume":"46","author":"Damholt","year":"2006","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.molmet.2020.101102_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.molmet.2020.101102_bib25","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.molmet.2020.101102_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.molmet.2020.101102_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17446651.2016.1113129","article-title":"Insulin degludec\/liraglutide (IDegLira) for the treatment of type 2 diabetes","volume":"11","author":"Gough","year":"2016","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib29","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/dom.12980","volume":"19","author":"Davies","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13479","article-title":"Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: a model-based approach","volume":"21","author":"Overgaard","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/dom.13935","article-title":"Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes","volume":"22","author":"Meier","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib35","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2337\/dc20-0498","article-title":"Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis","volume":"43","author":"Huthmacher","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib38","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/dc15-2479","article-title":"Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial","volume":"39","author":"Nauck","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib41","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/dom.12804","article-title":"A\u00a0meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients","volume":"19","author":"Abd El Aziz","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/dom.12402","article-title":"Is insulin the most effective injectable antihyperglycemic therapy?","volume":"17","author":"Buse","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib47","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib50","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2337\/dc20-0498","article-title":"Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis","volume":"43","author":"Huthmacher","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrendo.2011.30","article-title":"Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?","volume":"7","author":"Nauck","year":"2011","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib53","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.12539","article-title":"Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"17","author":"Ahmann","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib54","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib55","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jdiacomp.2017.05.010","article-title":"Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: results over 52 weeks","volume":"31","author":"Leiter","year":"2017","journal-title":"Journal of Diabetic Complications"},{"key":"10.1016\/j.molmet.2020.101102_bib56","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib57","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib58","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like Peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib59","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib60","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/dom.13368","article-title":"More patients reach glycemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: a post hoc time-to-control analysis of LixiLan-O and LixiLan-L","volume":"20","author":"Frias","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13300-019-00735-7","article-title":"Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis","volume":"11","author":"Tabak","year":"2020","journal-title":"Diabetes Therapeutics"},{"key":"10.1016\/j.molmet.2020.101102_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A\u00a0role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2020.101102_bib63","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib64","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib66","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib67","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.molmet.2020.101102_bib68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3810\/pgm.2009.05.1997","article-title":"Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits","volume":"121","author":"Nauck","year":"2009","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/j.molmet.2020.101102_bib70","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"Journal of the American Medical Association"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.molmet.2020.101102_bib71","article-title":"Efficacy and safety of dulaglutide 3 mg and 4.5 mg vs. dulaglutide 1.5 mg: 52-week results from AWARD-11 (abstract 357-OR)","volume":"69","author":"Frias","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib72","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101102_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmet.2020.101102_bib74","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cmet.2016.04.006","article-title":"Parabrachial CGRP neurons control meal termination","volume":"23","author":"Campos","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib75","first-page":"E 376","article-title":"Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways","volume":"305","author":"Nishizawa","year":"2013","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.molmet.2020.101102_bib76","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"issue":"Suppl 2","key":"10.1016\/j.molmet.2020.101102_bib77","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/ijo.2009.67","article-title":"The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation","volume":"33","author":"Di Marzo","year":"2009","journal-title":"International Journal of Obesity (Lond)"},{"key":"10.1016\/j.molmet.2020.101102_bib78","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib79","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in energy expenditure resulting from altered body weight","volume":"332","author":"Leibel","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib80","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib81","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.2337\/db14-1718","article-title":"Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system","volume":"64","author":"Daniele","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib82","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.molmet.2020.101102_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119034","article-title":"Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system","volume":"10","author":"Richard","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.molmet.2020.101102_bib84","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib85","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/dom.13764","article-title":"Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin","volume":"21","author":"Frias","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib86","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib87","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A\u00a0randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib88","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib89","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/dc12-1925","article-title":"Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity","volume":"36","author":"Schlogl","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib90","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11096-015-0219-8","article-title":"The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour","volume":"38","author":"de Boer","year":"2016","journal-title":"International Journal of Clinical Pharmacy"},{"key":"10.1016\/j.molmet.2020.101102_bib91","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12900","article-title":"Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: a randomized double-blind placebo-controlled clinical trial","volume":"19","author":"Jorgensen","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib92","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.molmet.2020.101102_bib93","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib94","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/dom.12534","article-title":"Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study","volume":"17","author":"Miyagawa","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib95","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib97","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib98","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib99","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib100","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib102","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A\u00a0critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.molmet.2020.101102_bib103","doi-asserted-by":"crossref","first-page":"S 245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk?","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib104","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib105","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib106","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2337\/dc16-0984","article-title":"Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide","volume":"40","author":"Nauck","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib107","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.molmet.2020.101102_bib108","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib109","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tem.2019.07.004","article-title":"Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials","volume":"30","author":"Caruso","year":"2019","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib111","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.molmet.2020.101102_bib112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.molmet.2020.101102_bib113","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.molmet.2020.101102_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","author":"Marsico","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.molmet.2020.101102_bib115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.molmet.2020.101102_bib116","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.molmet.2020.101102_bib117","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND (abstract 924-P)","volume":"69","author":"Colhoun","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib118","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib119","doi-asserted-by":"crossref","first-page":"154272","DOI":"10.1016\/j.metabol.2020.154272","article-title":"Commentary: glucose control: not just a bystander in GLP-1RA-mediated cardiovascular protection","volume":"109","author":"Caruso","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib120","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib121","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib122","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib123","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib124","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.molmet.2020.101102_bib125","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib127","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2174\/0929867326666190911141951","article-title":"The role of the endothelium in premature atherosclerosis: molecular mechanisms","volume":"27","author":"Spartalis","year":"2020","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.molmet.2020.101102_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054518","article-title":"DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes","volume":"8","author":"Ku","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.molmet.2020.101102_bib129","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.dsx.2019.01.031","article-title":"Association of fasting glucagon-like peptide-1 with oxidative stress and subclinical atherosclerosis in type 2 diabetes","volume":"13","author":"Alharby","year":"2019","journal-title":"Diabetes, Metabolic Syndrome"},{"key":"10.1016\/j.molmet.2020.101102_bib130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thrombosis & Haemostasis"},{"key":"10.1016\/j.molmet.2020.101102_bib131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-015-0852-y","article-title":"Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor kappaB signaling pathways","volume":"53","author":"Tang","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.molmet.2020.101102_bib132","article-title":"Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate pulmonary arterial hypertension through Drp1\/NOX- and Atg-5\/Atg-7\/Beclin-1\/LC3beta pathways","volume":"20","author":"Wu","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.molmet.2020.101102_bib133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.molmet.2020.101102_bib134","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2013.06.035","article-title":"LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells","volume":"437","author":"Dai","year":"2013","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.molmet.2020.101102_bib135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmet.2020.101102_bib136","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.molmet.2020.101102_bib137","doi-asserted-by":"crossref","first-page":"117531","DOI":"10.1016\/j.lfs.2020.117531","article-title":"Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats","volume":"250","author":"Li","year":"2020","journal-title":"Life Sciences"},{"key":"10.1016\/j.molmet.2020.101102_bib138","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1734-1140(13)71069-7","article-title":"Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells","volume":"65","author":"Dorecka","year":"2013","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.molmet.2020.101102_bib139","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","article-title":"Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor","volume":"325","author":"Erdogdu","year":"2010","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib140","first-page":"E 947","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.molmet.2020.101102_bib141","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.molmet.2020.101102_bib142","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear Factor-kappa B activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.molmet.2020.101102_bib143","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib144","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacologica Sinica"},{"issue":"5","key":"10.1016\/j.molmet.2020.101102_bib145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.molmet.2020.101102_bib146","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib147","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E-deficient mice via regulation of immune cell phenotypes and proinflammatory mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.molmet.2020.101102_bib148","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jdi.12446","article-title":"Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals","volume":"7","author":"Hirano","year":"2016","journal-title":"Journal of Diabetes Investigations"},{"key":"10.1016\/j.molmet.2020.101102_bib149","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A\u00a0glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.molmet.2020.101102_bib151","doi-asserted-by":"crossref","first-page":"BR 286","DOI":"10.12659\/MSM.883207","article-title":"Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis","volume":"18","author":"Zhan","year":"2012","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.molmet.2020.101102_bib152","doi-asserted-by":"crossref","first-page":"107748","DOI":"10.1016\/j.neuropharm.2019.107748","article-title":"The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke","volume":"158","author":"Yang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.molmet.2020.101102_bib153","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2013.08.033","article-title":"Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe\u207b\/\u207b mice","volume":"231","author":"Burgmaier","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmet.2020.101102_bib154","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2017.06.920","article-title":"Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: serial in\u00a0vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits","volume":"265","author":"Sudo","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmet.2020.101102_bib155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2012.11.057","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury","volume":"699","author":"Hirata","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.molmet.2020.101102_bib156","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmet.2020.101102_bib157","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","article-title":"Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study","volume":"15","author":"Rizzo","year":"2016","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.molmet.2020.101102_bib158","doi-asserted-by":"crossref","first-page":"108667","DOI":"10.1016\/j.biopha.2019.108667","article-title":"Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP\/PKA mediated down-regulation of MLC phosphorylation","volume":"113","author":"Tang","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.molmet.2020.101102_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.molmet.2020.101102_bib160","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Translational Science"},{"issue":"2","key":"10.1016\/j.molmet.2020.101102_bib161","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12317","article-title":"Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor \u03b1-mediated activation","volume":"36","author":"Garczorz","year":"2018","journal-title":"Cardiovascular Therapeutics"},{"key":"10.1016\/j.molmet.2020.101102_bib162","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.07.007","article-title":"Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"288","author":"Anholm","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmet.2020.101102_bib163","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/db14-1149","article-title":"Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment","volume":"64","author":"Balestrieri","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib164","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib166","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib167","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib168","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/PPA.S151736","article-title":"Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement","volume":"12","author":"Giorgino","year":"2018","journal-title":"Patient Preference and Adherence"},{"key":"10.1016\/j.molmet.2020.101102_bib169","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2337\/dc16-2725","article-title":"Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes","volume":"40","author":"Carls","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib170","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","article-title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide","volume":"19","author":"Alatorre","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib171","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/DMSO.S99732","article-title":"Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany","volume":"9","author":"Qiao","year":"2016","journal-title":"Diabetes Metabolism Syndrome Obesity"},{"key":"10.1016\/j.molmet.2020.101102_bib172","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.molmet.2020.101102_bib173","article-title":"Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data","author":"Mody","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib174","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.13160","article-title":"Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"McGovern","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/diaspect.28.4.283","article-title":"Injection-site nodules associated with the use of exenatide extended-release reported to the U.S. Food and drug administration adverse event reporting system","volume":"28","author":"Jones","year":"2015","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.molmet.2020.101102_bib176","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) group","volume":"281","author":"Turner","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.molmet.2020.101102_bib177","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system","volume":"145","author":"Brubaker","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib178","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/db08-1651","article-title":"Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice","volume":"58","author":"Tschen","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib179","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2337\/db07-1369","article-title":"Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans","volume":"57","author":"Meier","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib181","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.molmet.2020.101102_bib182","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12875-016-0543-7","article-title":"Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists","volume":"17","author":"Laux","year":"2016","journal-title":"BMC Family Practice"},{"key":"10.1016\/j.molmet.2020.101102_bib183","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-019-00833-1","article-title":"Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review","volume":"37","author":"Hong","year":"2019","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.molmet.2020.101102_bib184","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/DMSO.S71923","article-title":"Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment","volume":"8","author":"Kruger","year":"2015","journal-title":"Diabetes Metabolism Syndrome Obesity"},{"key":"10.1016\/j.molmet.2020.101102_bib185","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metabolism Research Reviews"},{"key":"10.1016\/j.molmet.2020.101102_bib186","doi-asserted-by":"crossref","first-page":"37787","DOI":"10.1074\/jbc.M106692200","article-title":"A\u00a0small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain","volume":"276","author":"Tibaduiza","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2020.101102_bib187","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1016\/j.bmcl.2007.06.086","article-title":"Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor","volume":"17","author":"Teng","year":"2007","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.molmet.2020.101102_bib188","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2337\/db10-0689","article-title":"Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets","volume":"59","author":"Sloop","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib189","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bph.12895","article-title":"The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating beta-endorphin release from spinal microglia","volume":"172","author":"Fan","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.molmet.2020.101102_bib190","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db10-1790","article-title":"Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function","volume":"60","author":"Kielgast","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib191","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients","volume":"19","author":"Creutzfeldt","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib192","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diab.44.6.626","article-title":"Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM","volume":"44","author":"Dupr\u00e9","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib193","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1210\/jc.2003-032001","article-title":"Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes","volume":"89","author":"Dupr\u00e9","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib194","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007791","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study","volume":"5","author":"Dejgaard","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.molmet.2020.101102_bib195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib196","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib197","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib198","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib199","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","article-title":"Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data","volume":"7","author":"Dennis","year":"2019","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib200","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib201","doi-asserted-by":"crossref","first-page":"154045","DOI":"10.1016\/j.metabol.2019.154045","article-title":"Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure","volume":"104","author":"Giorgino","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib202","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib203","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib204","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13300-019-0604-8","article-title":"Safety and efficacy of empagliflozin as add-on therapy to GLP-1 receptor agonist (liraglutide) in Japanese patients with type 2 diabetes mellitus: a randomised, double-blind, parallel-group phase 4 study","volume":"10","author":"Terauchi","year":"2019","journal-title":"Diabetes Therapeutics"},{"key":"10.1016\/j.molmet.2020.101102_bib205","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2337\/dc18-2460","article-title":"Combination therapy with canagliflozin plus liraglutide exerts additive effect on weight loss, but not on HbA1c, in patients with type 2 diabetes","volume":"43","author":"Ali","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib206","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.molmet.2020.101102_bib207","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinology"},{"issue":"6","key":"10.1016\/j.molmet.2020.101102_bib208","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib209","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.molmet.2020.101102_bib210","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib211","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","author":"Baggio","year":"2020","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib212","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc10-0200","article-title":"Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study","volume":"33","author":"Sathananthan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101102_bib213","doi-asserted-by":"crossref","DOI":"10.1089\/dna.2020.5424","article-title":"GLP1R single-nucleotide polymorphisms rs3765467 and rs10305492 affect beta cell insulin secretory capacity and apoptosis through GLP-1","author":"Li","year":"2020","journal-title":"DNA and Cell Biology"},{"key":"10.1016\/j.molmet.2020.101102_bib214","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3389\/fphys.2018.01331","article-title":"A\u00a0pilot study investigating the influence of glucagon-like peptide-1 receptor single nucleotide polymorphisms on gastric emptying rate in caucasian men","volume":"9","author":"Yau","year":"2018","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.molmet.2020.101102_bib215","article-title":"Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study","volume":"30","author":"Chedid","year":"2018","journal-title":"Neuro-Gastroenterology and Motility"},{"key":"10.1016\/j.molmet.2020.101102_bib216","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00125-007-0753-6","article-title":"Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms","volume":"50","author":"Sch\u00e4fer","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2005.05.001","article-title":"A\u00a0human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness","volume":"130","author":"Beinborn","year":"2005","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.molmet.2020.101102_bib218","doi-asserted-by":"crossref","first-page":"176949","DOI":"10.1155\/2015\/176949","article-title":"Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes","volume":"2015","author":"Lin","year":"2015","journal-title":"Journal of Diabetes Research"},{"key":"10.1016\/j.molmet.2020.101102_bib219","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1574884713666180221121512","article-title":"Pharmacogenetics of glucagon-like peptide-1 agonists for the treatment of type 2 diabetes mellitus","volume":"12","author":"Karras","year":"2017","journal-title":"Current Clinical Pharmacology"},{"key":"10.1016\/j.molmet.2020.101102_bib220","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib221","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: theoretical and practical applications","volume":"27","author":"Holst","year":"2011","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.molmet.2020.101102_bib222","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","volume":"245","author":"Batista","year":"2018","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.molmet.2020.101102_bib223","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.molmet.2020.101102_bib224","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"International Journal of Obesity (Lond)"},{"key":"10.1016\/j.molmet.2020.101102_bib225","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/j.molmet.2020.101102_bib226","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrneurol.2009.217","article-title":"The use of PET in Alzheimer disease","volume":"6","author":"Nordberg","year":"2010","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.molmet.2020.101102_bib227","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.molmet.2020.101102_bib228","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/bs.pbr.2019.10.008","article-title":"Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: rationale and clinical experience","volume":"252","author":"Foltynie","year":"2020","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.molmet.2020.101102_bib229","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2020.101102_bib230","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101102_bib231","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101102_bib232","first-page":"Cd 012990","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.molmet.2020.101102_bib233","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","article-title":"Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101102_bib234","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.molmet.2020.101102_bib235","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101102_bib236","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","article-title":"Improvement of psoriasis during exenatide treatment in a patient with diabetes","volume":"38","author":"Buysschaert","year":"2012","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.molmet.2020.101102_bib237","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.molmet.2020.101102_bib238","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.molmet.2020.101102_bib239","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:26:28Z","timestamp":1761956788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877820301769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":239,"alternative-id":["S2212877820301769"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101102"}}